SCHEMBL5564904

SCHEMBL5564904

Cc1c(F)cc(F)cc1Nc1ncnc2c(C)cccc12

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.42
RET P07949 1/20 0.42
KIF5B P33176 1/20 0.42
MKNK1 Q9BUB5 1/20 0.41
TP53 P04637 2/20 0.41
CFTR P13569 1/20 0.40
FLT1 P17948 2/20 0.39
FGFR1 P11362 1/20 0.39
EGFR P00533 2/20 0.39
ABCG2 Q9UNQ0 1/20 0.39
RPS6KB1 P23443 4/20 0.38
AURKA O14965 2/20 0.38
PTK2 Q05397 1/20 0.38
PDPK1 O15530 1/20 0.38
RAF1 P04049 1/20 0.37
BRAF P15056 1/20 0.37
MAPT P10636 1/20 0.37
AURKB Q96GD4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5570053 0.77 HPGD (0.52) FGFR1EGFRABCG2MAPT
SCHEMBL5568131 0.75 HTT (0.56) KDRRETKIF5BFLT1FGFR1
SCHEMBL5569119 0.74 TP53 (0.50) KDRRETKIF5BTP53EGFR
SCHEMBL5569131 0.72 RET (0.48) KDRRETKIF5BTP53EGFR
SCHEMBL5569470 0.72 EGFR (0.58) KDRRETEGFRABCG2AURKB
SCHEMBL5564423 0.71 HTT (0.56) KDRRETKIF5BEGFRMAPT
SCHEMBL5565218 0.71 BRD4 (0.50) KDRRETKIF5BTP53EGFR
SCHEMBL5564600 0.70 EGFR (0.43) EGFRABCG2RPS6KB1AURKAMAPT
SCHEMBL148097 0.70 EGFR (0.45) KDRMKNK1TP53FLT1FGFR1
SCHEMBL5568231 0.69 EGFR (0.64) MKNK1TP53EGFRRAF1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP claimed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT KDR 2712/4885RET 2776/4885KIF5B 2469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.